CERUS Announces the Acquisition of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA
- Transaction enables Opocrin to become a leading global producer of active biologics including heparin and heparinoids -
LA JOLLA, Calif. and DUBAI, United Arab Emirates, April 29, 2020 /PRNewswire/ -- Cerus Advisors DMCC, (CERUS), a boutique family office management firm, announced the acquisition of 100% of the stock of Laboratori Derivati Organici SpA (LDO) by Opocrin SpA ("Opocrin"), a global manufacturer of Active Pharmaceutical Ingredients ("API"). LDO, the flagship holding in the life sciences vertical of the CERUS family office portfolio, is a leading global company focused on the production of biological active pharmaceutical ingredients derived from animal origin. The product portfolio of LDO includes heparin, which is a widely used medication that prevents the formation of blood clots, along with a series of other specialized biological APIs.
"Cerus Advisors has dedicated significant time and resources to the development of LDO over the last 9 years and this transaction represents the culmination of these efforts," said Marios Fotiadis, M.B.A., Chairman, Manager Partner. "We are also pleased with the creation of a group that has significant potential for continued value creation for its shareholders."
This transaction represents a significant step forward for Opocrin, making the company bigger, stronger and more competitive in a context where business-size is essential to face more and more ambitious challenges while continuing to offer the highest quality active biologic products. The new corporate entity born from the transaction will now have three state of the art production facilities in Italy, as well as one in Mexico, that in combination with the joint ventures in South America and China, will employee over 270 people globally. This positions Opocrin as one of the main producers of heparin and its derivatives worldwide, with an expected 2020 turnover higher than €170 million.
"When we founded Cerus, we intended to create a platform to generate strong financial results in a relatively short period while operationally and strategically guiding our portfolio companies," said Kleanthis G. Xanthopoulos, Ph.D., Managing General Partner. "We are pleased to have made a step towards realizing this vision with the LDO sale."
About Cerus Advisors
Cerus DMCC is the strategic advisory arm of a single-family office with global investments, focused on the pharmaceutical, medical device, health care and real estate industries. Cerus has leveraged its extensive investment and deal- making expertise to work with other family offices and third-party institutional investors to create valuable syndications around high-value growth opportunities. Cerus' investment philosophy is rooted in its DNA as a single-family office advisor – therefore, every transaction is viewed with only one objective: Long-Term Value Creation. To achieve this objective, Cerus has developed a highly customized advisory practice that guides its portfolio companies and global partners in seeking private equity investments, deploying private equity resources and structuring highly customized private transactions. Cerus has offices in Dubai, UAE and in La Jolla, California, USA. For more information, please visit www.cerusadvisors.com.
SOURCE Cerus Advisors DMCC
Share this article